Emerging therapeutics for ocular surface disease

Brett P. Bielory, Steven P. Shah, Terrence O'Brien, Victor L Perez Quinones, Leonard Bielory

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Purpose of review The present review provides an overview on the potential of different systemic and topical treatments in chronic forms of ocular allergy and dry eye disorder (DED). The impact on anterior surface of ocular inflammatory disorder encompasses an array of conditions, which are frequently underreported. This can contribute to underdiagnoses and ineffective management from healthcare providers such as an allergist and/or ophthalmologist who routinely provide care for these common disorders. Owing to the current limited therapeutic options, healthcare providers are routinely seeking alternative treatments that could facilitate effective management of the conditions. Recent findings Recent advances in immunopathophysiology of ocular surface disorders has provided new potential targets and therapeutic strategies for the treatment of DED and ocular allergy that may include various immunobiological modulators. These modulators have focused on regulating the Th1 and Th2 immunemediated inflammatory pathways that inhibit various cytokines (e.g. IL-1, IL-4, IL-5, IL-9, IL-13) antibodies (e.g. IgE), and other surface markers of various cell lines (e.g. activated T-lymphocytes, lymphocyte function-associated antigen-1). Summary Recent findings about the pathophysiology of DED and ocular allergy have led to the greater understanding of the molecular and cellular mechanisms of ocular surface diseases leading to the potential novel targets for immunomodulation of anterior surface ocular disorders. New topical glucocorticoids, leukotriene receptor antagonists, IL-1 antagonists, IL-5, IL-4/IL-13 antagonists, integrin antagonists, and quinolone derivatives appear to be encouraging.

Original languageEnglish (US)
Pages (from-to)477-486
Number of pages10
JournalCurrent Opinion in Allergy and Clinical Immunology
Volume16
Issue number5
DOIs
StatePublished - 2016

Fingerprint

Eye Diseases
Hypersensitivity
Therapeutics
Interleukin-13
Interleukin-5
Interleukin-1
Interleukin-4
Health Personnel
Interleukin-9
Leukotriene Antagonists
Lymphocyte Function-Associated Antigen-1
Immunomodulation
Quinolones
Glucocorticoid Receptors
Integrins
Immunoglobulin E
Cytokines
T-Lymphocytes
Cell Line
Antibodies

Keywords

  • Allergic conjunctivitis
  • dry eye disease
  • ocular allergy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Emerging therapeutics for ocular surface disease. / Bielory, Brett P.; Shah, Steven P.; O'Brien, Terrence; Perez Quinones, Victor L; Bielory, Leonard.

In: Current Opinion in Allergy and Clinical Immunology, Vol. 16, No. 5, 2016, p. 477-486.

Research output: Contribution to journalReview article

Bielory, Brett P. ; Shah, Steven P. ; O'Brien, Terrence ; Perez Quinones, Victor L ; Bielory, Leonard. / Emerging therapeutics for ocular surface disease. In: Current Opinion in Allergy and Clinical Immunology. 2016 ; Vol. 16, No. 5. pp. 477-486.
@article{4f3403b03a0d48ccab41dc9a18c1babf,
title = "Emerging therapeutics for ocular surface disease",
abstract = "Purpose of review The present review provides an overview on the potential of different systemic and topical treatments in chronic forms of ocular allergy and dry eye disorder (DED). The impact on anterior surface of ocular inflammatory disorder encompasses an array of conditions, which are frequently underreported. This can contribute to underdiagnoses and ineffective management from healthcare providers such as an allergist and/or ophthalmologist who routinely provide care for these common disorders. Owing to the current limited therapeutic options, healthcare providers are routinely seeking alternative treatments that could facilitate effective management of the conditions. Recent findings Recent advances in immunopathophysiology of ocular surface disorders has provided new potential targets and therapeutic strategies for the treatment of DED and ocular allergy that may include various immunobiological modulators. These modulators have focused on regulating the Th1 and Th2 immunemediated inflammatory pathways that inhibit various cytokines (e.g. IL-1, IL-4, IL-5, IL-9, IL-13) antibodies (e.g. IgE), and other surface markers of various cell lines (e.g. activated T-lymphocytes, lymphocyte function-associated antigen-1). Summary Recent findings about the pathophysiology of DED and ocular allergy have led to the greater understanding of the molecular and cellular mechanisms of ocular surface diseases leading to the potential novel targets for immunomodulation of anterior surface ocular disorders. New topical glucocorticoids, leukotriene receptor antagonists, IL-1 antagonists, IL-5, IL-4/IL-13 antagonists, integrin antagonists, and quinolone derivatives appear to be encouraging.",
keywords = "Allergic conjunctivitis, dry eye disease, ocular allergy",
author = "Bielory, {Brett P.} and Shah, {Steven P.} and Terrence O'Brien and {Perez Quinones}, {Victor L} and Leonard Bielory",
year = "2016",
doi = "10.1097/ACI.0000000000000309",
language = "English (US)",
volume = "16",
pages = "477--486",
journal = "Current Opinion in Allergy and Clinical Immunology",
issn = "1528-4050",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Emerging therapeutics for ocular surface disease

AU - Bielory, Brett P.

AU - Shah, Steven P.

AU - O'Brien, Terrence

AU - Perez Quinones, Victor L

AU - Bielory, Leonard

PY - 2016

Y1 - 2016

N2 - Purpose of review The present review provides an overview on the potential of different systemic and topical treatments in chronic forms of ocular allergy and dry eye disorder (DED). The impact on anterior surface of ocular inflammatory disorder encompasses an array of conditions, which are frequently underreported. This can contribute to underdiagnoses and ineffective management from healthcare providers such as an allergist and/or ophthalmologist who routinely provide care for these common disorders. Owing to the current limited therapeutic options, healthcare providers are routinely seeking alternative treatments that could facilitate effective management of the conditions. Recent findings Recent advances in immunopathophysiology of ocular surface disorders has provided new potential targets and therapeutic strategies for the treatment of DED and ocular allergy that may include various immunobiological modulators. These modulators have focused on regulating the Th1 and Th2 immunemediated inflammatory pathways that inhibit various cytokines (e.g. IL-1, IL-4, IL-5, IL-9, IL-13) antibodies (e.g. IgE), and other surface markers of various cell lines (e.g. activated T-lymphocytes, lymphocyte function-associated antigen-1). Summary Recent findings about the pathophysiology of DED and ocular allergy have led to the greater understanding of the molecular and cellular mechanisms of ocular surface diseases leading to the potential novel targets for immunomodulation of anterior surface ocular disorders. New topical glucocorticoids, leukotriene receptor antagonists, IL-1 antagonists, IL-5, IL-4/IL-13 antagonists, integrin antagonists, and quinolone derivatives appear to be encouraging.

AB - Purpose of review The present review provides an overview on the potential of different systemic and topical treatments in chronic forms of ocular allergy and dry eye disorder (DED). The impact on anterior surface of ocular inflammatory disorder encompasses an array of conditions, which are frequently underreported. This can contribute to underdiagnoses and ineffective management from healthcare providers such as an allergist and/or ophthalmologist who routinely provide care for these common disorders. Owing to the current limited therapeutic options, healthcare providers are routinely seeking alternative treatments that could facilitate effective management of the conditions. Recent findings Recent advances in immunopathophysiology of ocular surface disorders has provided new potential targets and therapeutic strategies for the treatment of DED and ocular allergy that may include various immunobiological modulators. These modulators have focused on regulating the Th1 and Th2 immunemediated inflammatory pathways that inhibit various cytokines (e.g. IL-1, IL-4, IL-5, IL-9, IL-13) antibodies (e.g. IgE), and other surface markers of various cell lines (e.g. activated T-lymphocytes, lymphocyte function-associated antigen-1). Summary Recent findings about the pathophysiology of DED and ocular allergy have led to the greater understanding of the molecular and cellular mechanisms of ocular surface diseases leading to the potential novel targets for immunomodulation of anterior surface ocular disorders. New topical glucocorticoids, leukotriene receptor antagonists, IL-1 antagonists, IL-5, IL-4/IL-13 antagonists, integrin antagonists, and quinolone derivatives appear to be encouraging.

KW - Allergic conjunctivitis

KW - dry eye disease

KW - ocular allergy

UR - http://www.scopus.com/inward/record.url?scp=84987850978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987850978&partnerID=8YFLogxK

U2 - 10.1097/ACI.0000000000000309

DO - 10.1097/ACI.0000000000000309

M3 - Review article

C2 - 27585059

AN - SCOPUS:84987850978

VL - 16

SP - 477

EP - 486

JO - Current Opinion in Allergy and Clinical Immunology

JF - Current Opinion in Allergy and Clinical Immunology

SN - 1528-4050

IS - 5

ER -